Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals develops therapeutic drug candidates for rare and orphan diseases, particularly conditions with no approved or limited treatments. Its lead candidate, QRX003, is a topical lotion being studied for Netherton Syndrome and Peeling Skin Syndrome. The company also has QRX008, a potential treatment for scleroderma, and QRX009, a program developing topical rapamycin formulations for rare diseases. Quoin has research agreements with Queensland University of Technology and University College Cork, and commercial partnerships for QRX003 covering 61 countries outside its core territories. Quoin has not commercialized products or generated revenue. It plans to commercialize approved products directly in the U.S., Europe and Japan, and use partners in other markets. Its business includes developing product candidates and pursuing licensing, research partnerships and other transactions to expand its pipeline. Quoin’s headquarters are in Ashburn, Virginia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $QNRX in the last 7 days.
No SEC Form 4 filings for $QNRX in the last 30 days.
See all $QNRX insider activity →Quoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric case improved from severe (IGA 4) to clear (IGA 0) in eight months. The patient maintained IGA 0 for 21 months with no adverse events. Phase 2/3 trial interim results showed 66.7% met the primary endpoint. Topline data is expected in Q2 2027.
Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of
Quoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric patient with Netherton Syndrome maintained clear skin and no itching for 21 months. The company is in late-stage trials for the rare dermatology treatment, with Phase 2/3 results expected in Q2 2027.
Recent QNRX coverage spans technology, financial news and regulation.
Positive early‑stage data may lift the stock as investors price in higher efficacy expectations.
Positive clinical evidence is likely to lift sentiment and support a price rally.
Positive clinical data likely lifts sentiment and may drive the stock higher.
Positive trial data and analyst initiation suggest potential upside.
Positive regulatory milestone likely to lift the stock.
AlphAI scores every news story that mentions QNRX with an AI model for sentiment and relevance, and aggregates insider trades from Quoin Pharmaceuticals Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Quoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric case improved from severe (IGA 4) to clear (IGA 0) in eight months. The patient maintained IGA 0 for 21 months with no adverse events. Phase 2/3 trial interim results showed 66.7% met the primary endpoint. Topline data is expected in Q2 2027.
1 min readQuoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of
2 min readQuoin Pharmaceuticals (QNRX) published a peer-reviewed paper on QRX003, showing a pediatric patient with Netherton Syndrome maintained clear skin and no itching for 21 months. The company is in late-stage trials for the rare dermatology treatment, with Phase 2/3 results expected in Q2 2027.
1 min readCanaccord Genuity initiated coverage on Quoin Pharmaceuticals (QNRX) with a buy rating and $18 price target, citing its lead drug QRX003 for Netherton syndrome. The stock is down 74% over a year. Phase 2/3 study met primary endpoint, with topline data expected in 2027. Canaccord projects 2028 launch and $300M peak sales. BTIG also initiated coverage with a buy rating and $14 target.
1 min readQuoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug
2 min readQuoin Pharmaceuticals (QNRX) announced that its lead product QRX003 received Orphan Drug Designation in Europe for treating Peeling Skin Syndrome. This designation provides 10 years of market exclusivity upon approval and includes benefits like fee reductions and access to EU grants. The company plans to initiate the first formal clinical trial for Peeling Skin Syndrome by year-end. QRX003 has also received multiple regulatory designations for Netherton Syndrome in the US, Europe, and Japan.
2 min readBTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and $14 price target, implying a 211.1% upside from the Oct 9 close of $4.50. The firm cited strong clinical data for QRX003 in treating Netherton Syndrome and a significant market opportunity exceeding $3 billion.
1 min readQuoin Pharmaceuticals (QNRX) announced a paper on QRX003 was accepted by Dermatology and Therapy, citing interim Phase 2/3 data where 4/6 patients met the primary IGA endpoint. Compassionate-use updates showed improvements with no treatment-related adverse events reported.
2 min readQuoin Pharmaceuticals (QNRX) announced a peer-reviewed paper on QRX003, its investigational treatment for Netherton Syndrome, was accepted by Dermatology and Therapy. The paper details QRX003's mechanism and a case report of a pediatric patient's positive response. Quoin also reported interim Phase 2/3 study results, with 66.7% of participants achieving the primary endpoint. QRX003 has received Orphan Drug and Fast Track designations.
2 min readChange Agents Corp. (CHGA) launched a subsidiary for AI-enabled counter-drone tech and added a retired general to its advisory board. Quoin Pharmaceuticals (QNRX) reported positive Phase 2/3 trial data for QRX003 and raised $50M. Myseum.AI (MYSE) partnered with Fujifilm for print-on-demand products. Linkers Industries (LNKS) increased its stake in LPW Electronics, boosting its Thai operations.
3 min read
